Teriparatide U.S. label context · version 1
This page preserves this version's wording and source pins. Open the current profile →
What does the U.S. product label say?
Teriparatide injection · Read September 15, 2026 · Preserved label summary 1
Which population and use does the label cover?
The label covers specified high-fracture-risk osteoporosis settings in postmenopausal women, men with primary or hypogonadal osteoporosis, and men or women with glucocorticoid-associated osteoporosis. The male indication refers to increasing bone mass; the postmenopausal account includes fracture-risk reduction. Label: 1 ↗
Which safety limits matter?
The label contraindicates hypersensitivity and addresses osteosarcoma risk, hypercalcemia, cutaneous calcification including calciphylaxis, urinary stones and orthostatic hypotension. It distinguishes the rat osteosarcoma finding from observational human studies in which an increased risk was not observed. Label: 4, 5 ↗
Label edition and source pins
U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.
Teriparatide injection, solution · SPL version 9 · published 2026-06-30
Label ZIP SHA-256: 3d44d13e5c26a6d99016811b324c701e16b0d18d7390d19dd9e3ee5833bb6cb8. Extracted XML SHA-256: a86aaababbba9a8a6ddf6737fbd40d6ecf891c291bb211b5722997e127bf509b.